Search hospitals > Nevada > Carson City
Carson Tahoe Regional Medical Center
Claim this profileCarson City, Nevada 89703
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Adenocarcinoma
130 reported clinical trials
2 medical researchers
Summary
Carson Tahoe Regional Medical Center is a medical facility located in Carson City, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. Carson Tahoe Regional Medical Center is involved with conducting 130 clinical trials across 313 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
147 reported clinical trials
225 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation7 years of reported clinical research
Expert in Tumors
Expert in Leukemia
52 reported clinical trials
109 drugs studied
Clinical Trials running at Carson Tahoe Regional Medical Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Anal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Carson Tahoe Regional Medical Center?
Carson Tahoe Regional Medical Center is a medical facility located in Carson City, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. Carson Tahoe Regional Medical Center is involved with conducting 130 clinical trials across 313 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.